Chromocell Therapeutics Corp.(CHRO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CHRO Chromocell Therapeutics Corp.

Trading 12-27 14:21:48 EST

0.6310

-0.0291

-4.41%

High0.6600	Low0.6300	Vol26.98K
Open0.6310	D1 Closing0.6601	Amplitude4.54%
Mkt Cap3.80M	Tradable Cap1.00M	Total Shares6.03M
T/O17.14K	T/O Rate1.70%	Tradable Shares1.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CHRO","market":"US","secType":"STK","nameCN":"Chromocell Therapeutics Corp.","latestPrice":0.631,"timestamp":1735324185844,"preClose":0.6601,"halted":0,"volume":26981,"delay":0,"floatShares":1587084,"shares":6028011,"eps":-2.204187,"marketStatus":"Trading","change":-0.0291,"latestTime":"12-27 14:21:48 EST","open":0.631,"high":0.66,"low":0.63,"amount":17144.05548896,"amplitude":0.045448,"askPrice":0.689,"askSize":100,"bidPrice":0.5922,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.204187,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1735333200000},"marketStatusCode":2,"adr":0,"listingDate":1708059600000,"exchange":"AMEX","adjPreClose":0.6601,"preHourTrading":{"tag":"盘前","latestPrice":0.6899,"preClose":0.6601,"latestTime":"09:23 EST","volume":520,"amount":358.612592,"timestamp":1735309388795},"postHourTrading":{"tag":"盘后","latestPrice":0.6986,"preClose":0.6601,"latestTime":"18:47 EST","volume":1607,"amount":1113.284,"timestamp":1735256867182},"volumeRatio":0.434754},"requestUrl":"/m/hq/s/CHRO/wiki","defaultTab":"wiki","newsList":[{"id":"2492449779","title":"Channel Therapeutics highlights difference between NaV1.7, NaV1.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2492449779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492449779?lang=en_us&edition=fundamental","pubTime":"2024-12-20 22:16","pubTimestamp":1734704168,"startTime":"0","endTime":"0","summary":"Channel Therapeutics (CHRO) is providing a statement regarding Vertex Pharmaceutical’s (VRTX) recently announced Phase 2 data of Suzetrigine, an in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/channel-therapeutics-highlights-difference-between-nav1-7-nav1-8?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/channel-therapeutics-highlights-difference-between-nav1-7-nav1-8?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2462157665.USD","LU0058720904.USD","VRTX","IE0009355771.USD","LU0256863811.USD","IE00B19Z9P08.USD","LENZ","BK4567","CHRO","BK4585","LU0079474960.USD","IE00BFTCPJ56.SGD","LU0417517546.SGD","LU2237438978.USD","LU0823416689.USD","LU1585245621.USD","VERX","BK4532","IE0002141913.USD","LU1093756168.USD","LU2362541513.USD","IE00B4R5TH58.HKD","LU0109394709.USD","LU1035775433.USD","IE00B19Z3581.USD","IE00B19Z9Z06.USD","LU2324357040.USD","BK4588","BK4023","IE00BJT1NW94.SGD","LU0061475181.USD","IE0002270589.USD","LU1430594728.SGD","LU2456880835.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0234570918.USD","LU0566484027.USD","LU1069344957.HKD","LU2417539215.USD","LU2362540622.SGD","LU0889565916.HKD","IE00B894F039.SGD","LU1559883803.SGD","LU1093756325.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BZ9MQY76.HKD","LU0320765992.SGD","BK4139"],"gpt_icon":0},{"id":"2492058901","title":"How the CHRO of Kyndryl reinvented corporate culture for 80,000 workers after spinning off from IBM","url":"https://stock-news.laohu8.com/highlight/detail?id=2492058901","media":"Fortune","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492058901?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:30","pubTimestamp":1734615011,"startTime":"0","endTime":"0","summary":"When Maryjo Charbonnier started working for tech giant IBM in 2021, she was asked to tackle a project that would be daunting for any HR professional: spinning off an entirely new company.IBM announced in 2020 that it would be turning its managed infrastructure services division into a new public company called Kyndryl. To do so, Charbonnier had to transition around 80,000 employees to the new enterprise, establish a new organizational chart, overhaul existing processes, and reimage a new culture. And she had two years to complete the mission.“During those initial days, I felt like I ran the world's largest emergency room instead of an HR department,” Charbonnier tells Fortune. “There was constant chaos.”During those initial days, I felt like I ran the world's largest emergency room instead of an HR department. There was constant chaos. I had to find new brand leaders, build a new org chart, and ensure our processes were set up efficiently, all while handling a massive amount of transac","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9YsgUNm49MgXm6jJXBHtNg--~B/aD0xMTU2O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/1d8c94dc25a16b2b4789a1005c145431","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9YsgUNm49MgXm6jJXBHtNg--~B/aD0xMTU2O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/1d8c94dc25a16b2b4789a1005c145431"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chro-kyndryl-reinvented-corporate-culture-133011169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4534","BK4579","BK4602","IE0031619046.USD","IE00B19Z4B17.USD","LU0321505868.SGD","IE00B66KJ199.SGD","LU1883839398.USD","LU1674673691.USD","LU1880398554.USD","BK4134","LU1880398471.USD","BK4139","BK4588","BK4533","LU1674673428.USD","IBM","BK4538","LU1430594728.SGD","LU0868494617.USD","BK4575","CHRO","KD","LU1585245621.USD","IE00B7SZL793.SGD","LU1778281490.HKD","LU0321505439.SGD"],"gpt_icon":0},{"id":"2492853191","title":"Channel Therapeutics Announces Positive Efficacy Data for a Depot Formulation of a Nav1.7 Inhibitor in a Preclinical in Vivo Nerve Block Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2492853191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492853191?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:30","pubTimestamp":1734528601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA6NYR7D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHRO","BK4139"],"gpt_icon":0},{"id":"2492370185","title":"Channel Therapeutics Corp - Achieves Endpoints in Pre-Clinical Pain Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2492370185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492370185?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:30","pubTimestamp":1734528601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA6NYR7D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CHRO"],"gpt_icon":0},{"id":"2492185377","title":"Channel Therapeutics Corp - Formulations Show Improvement Over Bupivacaine in Efficacy and Duration","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492185377?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:30","pubTimestamp":1734528601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA6NYR7D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CHRO"],"gpt_icon":0},{"id":"2490570663","title":"Norfolk Southern appoints Ann Adams as CHRO","url":"https://stock-news.laohu8.com/highlight/detail?id=2490570663","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490570663?lang=en_us&edition=fundamental","pubTime":"2024-12-10 02:05","pubTimestamp":1733767544,"startTime":"0","endTime":"0","summary":"Norfolk Southern (NSC) has named Ann Adams as Chief Human Resources Officer, with responsibility for human resources and labor relations, reporting...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/norfolk-southern-appoints-ann-adams-as-chro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/norfolk-southern-appoints-ann-adams-as-chro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","CHRO","LU0742534661.SGD","NSC","LU0187121727.USD","LU0251142724.SGD","LU2244417387.USD","LU0251131958.USD","LU1303367103.USD","BK4520","BK4588","BK4139","LU0048573561.USD","LU2098885051.SGD","BK4016"],"gpt_icon":0},{"id":"2486065324","title":"NIKE, Inc. Appoints Treasure Heinle as Executive Vice President and Chief Human Resources Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2486065324","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486065324?lang=en_us&edition=fundamental","pubTime":"2024-11-26 05:15","pubTimestamp":1732569300,"startTime":"0","endTime":"0","summary":"Monique Matheson, NIKE’s long-tenured Chief HR Officer, will retire after 26 years with the company. BEAVERTON, Ore., November 25, 2024----NIKE, Inc.  today announced a change to its Senior Leadership Team . Treasure Heinle, Chief Talent Officer, will become the company’s new Executive Vice President and Chief Human Resources Officer . In her new role, Heinle will be responsible for leading the global HR function and managing NIKE’s People vision and strategy. She succeeds Monique Matheson who has decided to retire from NIKE after 26 years with the company. This leadership change is effective January 6, 2025.NIKE, Inc., based near Beaverton, Oregon, is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel and equipment for a wide range of sports and fitness activities. Wholly-owned NIKE, Inc. subsidiary brands include Converse, which designs, markets and distributes athletic lifestyle footwear, apparel and accessories; and Jordan Brand, which de","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/D._5iJAHq_01czdF611kkw--~B/aD00ODA7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/87a130f3a05a5ba73293881c6f34aa57","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/D._5iJAHq_01czdF611kkw--~B/aD00ODA7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/87a130f3a05a5ba73293881c6f34aa57"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nike-inc-appoints-treasure-heinle-211500705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","LU0823411888.USD","BK4588","BK4139","BK4558","BK4561","BK4533","BK4585","CHRO","LU2098885051.SGD","LU0786609619.USD","SLT","GRO","BK4566","BK4534","LU1303367103.USD","BK4146","NKE"],"gpt_icon":1},{"id":"2485418787","title":"Chromocell changes name to Channel Therapeutics, provides program updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2485418787","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485418787?lang=en_us&edition=fundamental","pubTime":"2024-11-21 22:55","pubTimestamp":1732200928,"startTime":"0","endTime":"0","summary":"Chromocell Therapeutics (CHRO) announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation, along with reincorp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/chromocell-changes-name-to-channel-therapeutics-provides-program-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/chromocell-changes-name-to-channel-therapeutics-provides-program-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHRO","BK4139","LENZ"],"gpt_icon":0},{"id":"2485884490","title":"Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2485884490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485884490?lang=en_us&edition=fundamental","pubTime":"2024-11-21 22:49","pubTimestamp":1732200547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA8LLCYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHRO","BK4139"],"gpt_icon":0},{"id":"2485749228","title":"Chromocell Therapeutics Rebrands to Focus on Pain Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2485749228","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485749228?lang=en_us&edition=fundamental","pubTime":"2024-11-21 22:28","pubTimestamp":1732199319,"startTime":"0","endTime":"0","summary":"Chromocell Therapeutics Corp ( ($CHRO) ) just unveiled an update. Channel Therapeutics Corporation, formerly Chromocell Therapeutics, has rebranded...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chromocell-therapeutics-rebrands-to-focus-on-pain-treatments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chromocell-therapeutics-rebrands-to-focus-on-pain-treatments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHRO","LENZ","BK4139"],"gpt_icon":0},{"id":"2484113691","title":"YY Group Holding Celebrates Hong Ye Group’s Wins for Excellence in Workplace and Cleaning Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2484113691","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484113691?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:40","pubTimestamp":1732110000,"startTime":"0","endTime":"0","summary":"On November 15, Hong Ye Group was celebrated among Asia’s top employers at the HR Asia Best Companies to Work for in Asia 2024 awards ceremony at Marina Bay Sands, Singapore. Rachel Xu, Chief Human Resources Officer  of YY Group Holding Limited, proudly accepted the award on behalf of the company.Mike Fu, CEO of YY Group Holding Limited, expressed his gratitude for the recognition:\"We are thrilled to be named one of Asia's Best Companies to Work For. This achievement is a testament to our efforts in fostering a supportive and inclusive environment where every employee can thrive. We thank all our staff for their dedication and contributions, which have made this possible.\". Hong Ye Group, a subsidiary of YY Group Holding Limited, is renowned for its exceptional facility management services, catering to a wide range of sectors including hospitality, corporate, and healthcare. Known for its high standards and commitment to quality, Hong Ye Group continuously strives to enhance operationa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Tshu3P.F2DddUwTiSAWww--~B/aD00Njt3PTE1NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/f49022a8eb9f0b69bef6b767d4275da0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Tshu3P.F2DddUwTiSAWww--~B/aD00Njt3PTE1NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/f49022a8eb9f0b69bef6b767d4275da0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/yy-group-holding-celebrates-hong-134000414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CFO","BK4585","BK4077","BK4139","BK4526","BK4551","BK4503","BK4120","CHRO","YYGH","BK4023","BK4513","BK4535","BK4531","BK4588","YY"],"gpt_icon":1},{"id":"2484098075","title":"Chromocell Therapeutics Merges into Channel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2484098075","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484098075?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:27","pubTimestamp":1731968843,"startTime":"0","endTime":"0","summary":"Chromocell Therapeutics Corp ( ($CHRO) ) has provided an announcement. Chromocell Therapeutics Corporation has merged into its subsidiary, Channel ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chromocell-therapeutics-merges-into-channel-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chromocell-therapeutics-merges-into-channel-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHRO","LENZ","BK4139"],"gpt_icon":0},{"id":"2483713876","title":"Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483713876","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483713876?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":"– Clinical data from the RESET-Myositis and RESET-SLE trials, along with initial clinical data from the RESET-SSc trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 –。– 16 patients enrolled with 10 patientsdosed as of November 12 across the RESET clinical development program; 40 U.S. clinical sites actively recruiting patients –。– Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 –。– Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International –。PHILADELPHIA, Nov. 14, 2024  -- Cabaletta Bio, Inc. , a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2024, and pro","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cabaletta-bio-reports-third-quarter-120000573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4110","CHRO","BK4077","ACR","SLE","CABA","CTA"],"gpt_icon":0},{"id":"2479709345","title":"Gildan Reports Record Third Quarter Revenue and Adjusted Diluted EPS¹ and Updates its Full Year 2024 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2479709345","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479709345?lang=en_us&edition=fundamental","pubTime":"2024-10-31 18:45","pubTimestamp":1730371500,"startTime":"0","endTime":"0","summary":"(all amounts are in U.S. dollars except where otherwise indicated) (1) Please refer to \"Definition and reconciliation of non-GAAP financial measures\" in this press release  Record third quarter net sa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/31/2972425/0/en/Gildan-Reports-Record-Third-Quarter-Revenue-and-Adjusted-Diluted-EPS-and-Updates-its-Full-Year-2024-Guidance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSU","GSG","CHRO","BK4139"],"gpt_icon":0},{"id":"2479255409","title":"FirstEnergy names Karen McClendon CHRO","url":"https://stock-news.laohu8.com/highlight/detail?id=2479255409","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479255409?lang=en_us&edition=fundamental","pubTime":"2024-10-30 03:10","pubTimestamp":1730229015,"startTime":"0","endTime":"0","summary":"FirstEnergy (FE) announced that Karen McClendon has been named senior VP and chief human resources officer, or CHRO, effective November 11. McClend...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/firstenergy-names-karen-mcclendon-chro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/firstenergy-names-karen-mcclendon-chro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","FE","BK4585","CHRO","BK4139","BK4588"],"gpt_icon":0},{"id":"2479253922","title":"Press Release: FirstEnergy Names Karen McClendon Senior Vice President and Chief Human Resources Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2479253922","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479253922?lang=en_us&edition=fundamental","pubTime":"2024-10-30 03:00","pubTimestamp":1730228400,"startTime":"0","endTime":"0","summary":"AKRON, Ohio, Oct. 29, 2024 /PRNewswire/ -- FirstEnergy Corp.  announced today that Karen McClendon has been named Senior Vice President and Chief Human Resources Officer , effective Nov. 11.In this role, McClendon will spearhead efforts to integrate and advance the company's human capital strategy, ensuring alignment with the strategic vision to establish FirstEnergy as a premier electric company. She will oversee key human resources functions, including talent management, benefits and compensation, labor and employee relations, and the commitment to building an inclusive workforce and a workplace reflective of the communities served by FirstEnergy. McClendon will report to Brian Tierney, FirstEnergy President and Chief Executive Officer.McClendon joins FirstEnergy with more than three decades of human resources experience. She has a proven track record in developing solutions, delivering results, generating support across multiple levels, leading culture transformation and fostering a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHRO","FE","BK6046","BK4081","BK4585","SGR.SI","BK4139","BK4588"],"gpt_icon":0},{"id":"2479401331","title":"Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2479401331","media":"THOMSON REUTERS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479401331?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:30","pubTimestamp":1730205000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nTUA1ZG1WX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CHRO"],"gpt_icon":0},{"id":"2479404331","title":"Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2479404331","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479404331?lang=en_us&edition=fundamental","pubTime":"2024-10-29 20:30","pubTimestamp":1730205000,"startTime":"0","endTime":"0","summary":"FREEHOLD, N.J., Oct. 29, 2024  -- Chromocell Therapeutics Corporation , , a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company’s novel NaV1.7 molecule for treating chronic pain and eye pain.There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product.“We are leveraging our existing know-how and intellectual property to target different pain indications and methods of delivery in an efficient and synergistic manner. We are taking advantage of the extensive pre-clinical and Phase I studies performed with CC8464 demonstrating strong efficacy in a wide variety of preclinical models and no dose limiting tolerability conc","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vG6EFnuye1oelYdxvvrKeg--~B/aD0zODc7dz0yMDAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e23b1993816c00e8207377a6f632741c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vG6EFnuye1oelYdxvvrKeg--~B/aD0zODc7dz0yMDAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e23b1993816c00e8207377a6f632741c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chromocell-announces-unveiling-injectable-depot-123000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHRO"],"gpt_icon":0},{"id":"2477463826","title":"Chromocell Announces Amendment to Stock Repurchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2477463826","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477463826?lang=en_us&edition=fundamental","pubTime":"2024-10-24 20:45","pubTimestamp":1729773900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241024:nTUACBWVR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CHRO"],"gpt_icon":0},{"id":"2477635353","title":"Chromocell Announces Amendment to Stock Repurchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2477635353","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477635353?lang=en_us&edition=fundamental","pubTime":"2024-10-24 20:45","pubTimestamp":1729773900,"startTime":"0","endTime":"0","summary":"FREEHOLD, N.J., Oct. 24, 2024  -- Chromocell Therapeutics Corporation , , a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors  has authorized an amendment  to the Company’s existing stock repurchase plan  to increase the total value of shares of Chromocell’s common stock  available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000.In addition, the Amendment extends the termination date of the Repurchase Plan from December 31, 2024 to June 30, 2025.The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the Board of Directors at any time.Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sod","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vG6EFnuye1oelYdxvvrKeg--~B/aD0zODc7dz0yMDAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e23b1993816c00e8207377a6f632741c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vG6EFnuye1oelYdxvvrKeg--~B/aD0zODc7dz0yMDAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e23b1993816c00e8207377a6f632741c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chromocell-announces-amendment-stock-repurchase-124500441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHRO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chromocell.com","stockEarnings":[{"period":"1week","weight":0.0109},{"period":"1month","weight":0.1035},{"period":"3month","weight":-0.2142},{"period":"6month","weight":-0.4999},{"period":"1year","weight":-0.89},{"period":"ytd","weight":-0.89}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0523},{"period":"6month","weight":0.105},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.2652}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.","exchange":"AMEX","name":"Chromocell Therapeutics Corp.","nameEN":"Chromocell Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Chromocell Therapeutics Corp.(CHRO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Chromocell Therapeutics Corp.(CHRO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Chromocell Therapeutics Corp.,CHRO,Chromocell Therapeutics Corp.股票,Chromocell Therapeutics Corp.股票老虎,Chromocell Therapeutics Corp.股票老虎国际,Chromocell Therapeutics Corp.行情,Chromocell Therapeutics Corp.股票行情,Chromocell Therapeutics Corp.股价,Chromocell Therapeutics Corp.股市,Chromocell Therapeutics Corp.股票价格,Chromocell Therapeutics Corp.股票交易,Chromocell Therapeutics Corp.股票购买,Chromocell Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Chromocell Therapeutics Corp.(CHRO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Chromocell Therapeutics Corp.(CHRO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}